| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMED | Common Stock | Sale | -$25.7K | -100 | -0.23% | $257.35 | 42.8K | 25 May 2021 | Direct | F1, F2 |
| transaction | AMED | Common Stock | Sale | -$273K | -1.05K | -2.46% | $259.69 | 41.7K | 25 May 2021 | Direct | F1, F3 |
| transaction | AMED | Common Stock | Sale | -$26.1K | -100 | -0.24% | $260.78 | 41.6K | 25 May 2021 | Direct | F1 |
| holding | AMED | Common Stock | 279 | 25 May 2021 | Through 401(k) Plan | F4 |
| Id | Content |
|---|---|
| F1 | These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. |
| F2 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.35 to $257.36, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| F3 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.32 to $260.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. |
| F4 | The information in this report is based on a plan statement dated as of March 31, 2021. |